Our Chair Tom Weber passed away in September 2019. He was Academic Professor of Surgery and Cancer Epidemiology at the Donald and Barbara Zucker School of Medicine at Hofstra / Northwell in New York, Director of Surgical Oncology Services for the Western Region of Northwell Health and Medical Co-Director of the Cancer Genetics Programs in that region. Tom attended his first LCPG meeting in 1995 and was been a regular attendee and supporter through the development of the ICG-HNPCC and ultimately InSiGHT at its inception in 2005. He was also a former President of the Collaborative Group of the Americas.

Susan Parry is Associate Professor of Gastroenterology specialising in familial gastrointestinal cancers. She is the Clinical Director of the New Zealand Familial Gastrointestinal Cancer Service, and Clinical Director of the Ministry of Health Bowel Cancer Programme. Susan is a past President of the New Zealand Society of Gastroenterology and has been a member of InSiGHT since it began. She was a member of the predecessor organisations, the LCPG and ICG-HNPCC. Susan has been involved as an investigator in the Australasian Colorectal Cancer Family Study-Colon CFR for many years and has a research interest in the Serrated Polyposis Syndrome.

Gabriel Capella is Director of the Hereditary Cancer Program at the Catalan Institute of Oncology. He trained as a general and digestive surgeon in Barcelona, and is also accredited in Human Genetics by the Spanish Society of Human Genetics. His research focuses in the study of the genetic basis of gastrointestinal cancer with a particular interest in hereditary colorectal cancer.

Ian Frayling is Consultant in Genetic Pathology in Cardiff, Wales. His work now concentrates on mutation interpretation and systematic testing of incident cancers to identify hereditary cases. He is also an assessor for the UK National External Quality Assessment Scheme in Immunohistochemistry. He is a founder member of InSiGHT, InSiGHT’s Variant Interpretation Committee, and the Mallorca Group.

Nicoline Hoogerbrugge is Professor in Hereditary Cancer at Radboud University Medical Center, Nijmegen. She has been directly involved in identification of several genes involved in hereditary colorectal cancer, including EPCAM, BUB1, BUB3, FOCAD and recently NTHL1. She also works on dendritic cell vaccinations for cancer prevention in healthy carries of a Lynch syndrome mutation.

Matthew Kalady is Professor of Surgery at Cleveland Clinic and the Lerner College of Medicine at Case Western Reserve University. He is Vice-Chairman of the Department of Colorectal Surgery and has an active clinic practice treating patients with hereditary colorectal cancer syndromes. He is the Director of the Cleveland Clinic Sanford R Weiss Center for Hereditary Colorectal Neoplasia. In these roles, he has developed and overseen multidisciplinary clinical and research programs, and he has an extensive track record in both clinical and scientific publications on hereditary CRC syndromes. He has also served as the President of the Collaborative Group of the Americas on Hereditary Colorectal Cancer (2013-14).

Brandie Heald Leach is a genetic counsellor in the Genomic Medicine Institute and Sanford R Weiss Center for Hereditary Colorectal Neoplasia at Cleveland Clinic. She coordinates the Cleveland Clinic Universal Lynch Syndrome Screening Program and conducts research on the hamartomatous polyposis syndromes. She was on the board for Hereditary Colon Cancer Takes Guts, and is past president of the Collaborative Group of the Americas on Hereditary Colorectal Cancer. She is currently on the Board of Directors for the Lynch Syndrome Screening Network.

Andrew Latchford is Consultant Gastroenterologist at St Mark's Hospital and Honorary Senior Lecturer at Imperial College, London. He is Assistant Director of the St Mark's Hospital Polyposis Registry and currently supervises research on upper GI tract disease in polyposis syndromes, pouch polyps in FAP, serrated polyposis syndrome and identification/management outcomes in Lynch syndrome. He was an expert advisor to NICE in the development of guidelines for universal tumour MMR testing.

Patrick Lynch is Professor of Medicine, Department of Gastroenterology, Hepatology, Nutrition, University of Texas MD Anderson Cancer Centre. He has been a member of InSiGHT since its inception and was Co-chair 2009-11. He was a member of the predecessor organizations, the LCPG and ICG-HNPCC. His current interest is the development of a web-based platform for communication of risk information within mutation-positive families. He ran the 2016 New York Marathon to raise funds for InSiGHT.

Finlay Macrae is Professor in the Department of Medicine, University of Melbourne, Australia and Head of Colorectal Medicine and Genetics at The Royal Melbourne Hospital. He was a founding member of the antecedent Leeds Castle Polyposis Group, and instigated creation of the InSiGHT MMR database, its Variant Interpretation Committee, and the association with the Human Variome Project.

Allan Spigelman is Professor of Surgery at the University of New South Wales, and Director of St Vincent's Hereditary Cancer Clinic. He described the most widely used classification for upper gastrointestinal polyposis in FAP patients while a research fellow at St Mark’s Hospital. He has gone on to establish cancer genetic clinics across his state in Australia, and remains active in the cancer genetic research area. He was Chair of InSiGHT council and hosted the biennial meeting of InSiGHT in Cairns in 2013.